Core Viewpoint - Vaxart, Inc. is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirements following a trading suspension due to non-compliance [2][3][4] Group 1: Reverse Stock Split Proposal - The preliminary proxy statement includes a proposal for a reverse stock split with a ratio of not less than 1-for-5 and not more than 1-for-20 [9] - The proposal aims to reduce the number of authorized shares of common stock in proportion to the reverse stock split [4][9] - The Board of Directors believes that compliance with Nasdaq listing requirements is essential for liquidity and capital raising [3] Group 2: Stockholder Engagement - A special meeting of stockholders is scheduled for September 5, 2025, to discuss the reverse stock split proposal [5] - Management plans to hold a live stockholder fireside chat to address questions and explain the necessity of the reverse stock split [3][8] Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [6] - The company's vaccine candidates include those for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [6]

Core Insights - Lucid Motors received a significant boost with Uber Technologies announcing a $300 million investment to form a robotaxi partnership, leading to a stock increase of over 40% [1][3] - The partnership aims to deploy a fleet of 20,000 Lucid vehicles over the next six years, utilizing Lucid's Gravity SUV and Nuro's level 4 autonomy system [4][6] - Lucid's recent developments, including the potential reverse stock split, are aimed at enhancing its attractiveness to institutional investors [9][12] Investment Partnership - The collaboration with Uber involves creating a new robotaxi service that leverages Lucid's advanced vehicle technology and Uber's extensive global network [3][7] - The first prototype of the Lucid-Nuro robotaxi is already operational, indicating progress in the partnership [4] - This investment validates Lucid's technology and positions it favorably in the autonomous vehicle market, potentially increasing demand for its products [9][13] Production and Market Strategy - Lucid aims to deliver approximately 20,000 vehicles in 2025, a significant increase from the 6,500 vehicles delivered in the first half of the year [6] - The partnership with Uber is seen as a critical step in proving Lucid's technology and market demand, especially in comparison to competitors like Rivian [7][8] Reverse Stock Split - Lucid has filed for a reverse stock split at a ratio of 1:10, which will consolidate shares and increase the trading price without changing market capitalization [10][11] - This move is intended to make Lucid's stock more appealing to larger institutional investors who often have minimum price thresholds for investment [12] - While reverse stock splits are generally viewed negatively, Lucid's situation does not indicate immediate financial distress [11][13]

Core Viewpoint - Generation Bio Co. announced a 1-for-10 reverse stock split to increase the per-share market price and regain compliance with Nasdaq listing requirements [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 pm Eastern Time on July 21, 2025, and trading on a split-adjusted basis will begin on July 22, 2025 [1][2]. - The number of issued and outstanding shares will decrease from approximately 67.3 million to approximately 6.7 million [3]. - No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares [4]. Group 2: Company Background - Generation Bio is focused on developing therapeutics for T cell-driven autoimmune diseases using cell-targeted lipid nanoparticles to deliver small interfering RNA to T cells [7]. - The company's innovative approach aims to address historically undruggable disease-driving genes in autoimmunity [7].

Group 1 - Lucid's stock increased by 46.72% in premarket trading following Uber's announcement of a $300 million investment in the electric vehicle maker as part of a six-year robotaxi partnership [1][4] - Under the agreement, Uber will deploy at least 20,000 Lucid vehicles equipped with Nuro's self-driving technology over a six-year period, with the first robotaxis expected to launch in a major U.S. city next year [3][4] - The partnership marks a significant shift for Lucid from focusing on luxury consumer vehicles to entering the commercial robotaxi market [5] Group 2 - Lucid's first robotaxi prototype is currently being tested at Nuro's Las Vegas proving grounds, with the vehicles set to be owned and operated by Uber or its fleet partners [6] - Lucid filed a preliminary proxy statement with the SEC regarding a special stockholders' meeting to authorize a 1-for-10 reverse stock split, which the company believes will make its common stock more attractive to investors [7] - The reverse stock split will not affect stockholders' ownership interests or voting power, except for potential cash payments for fractional shares, and requires majority approval from votes cast at the special stockholders' meeting [8]

Core Points - Ikena Oncology, Inc. announced the results of its annual stockholder meeting, where stockholders approved the merger with Inmagene Biopharmaceuticals [2][3] - The combined company will be named ImageneBio, Inc. and will trade on Nasdaq under the ticker symbol "IMA" [3] - A 1-for-12 reverse stock split will be executed, reducing the number of outstanding shares from approximately 48.2 million to about 4 million [3][4] Company Overview - Ikena Oncology focuses on developing differentiated therapies targeting cancer growth, spread, and therapeutic resistance [6] - Inmagene Biopharmaceuticals is a clinical-stage biotechnology company developing therapeutics for immunological and inflammatory diseases, with its lead asset IMG-007 recently completing Phase 2a trials [5][6] Merger Details - The merger allows for the issuance of shares of Ikena's common stock to Inmagene shareholders and investors involved in the financing concurrent to the merger [3] - The reverse stock split is expected to be effective around the end of July, prior to the merger closing [3][4] - The new CUSIP number for the combined company's common stock will be 45175G 207 [3] Product Information - IMG-007 is a humanized, subcutaneously administered monoclonal antibody targeting OX40, showing promising results in clinical trials for atopic dermatitis and alopecia areata [7] - The drug demonstrated a half-life of 34.7 days, supporting infrequent dosing [7] - In clinical trials, IMG-007 exhibited sustained clinical activity and was well tolerated, with no significant adverse effects reported [7]

Core Viewpoint - Passage Bio, Inc. has announced a reverse stock split at a ratio of 1-for-20 to comply with Nasdaq's minimum bid price requirement of $1.00 per share, effective July 14, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 62,405,898 to about 3,120,295 [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's equity awards and incentive plans [2]. - The reverse stock split will not change the number of authorized shares or the par value per share [2]. Group 2: Stockholder Information - Registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares [3]. - Stockholders with shares in brokerage accounts will have their positions automatically adjusted, with no action required on their part [3]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive the nearest whole share [3]. Group 3: Company Overview - Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases [4]. - The lead product candidate, PBFT02, aims to treat conditions like frontotemporal dementia by elevating progranulin levels [4].

Core Points - CLS Holdings USA, Inc. announced a reverse stock split of one post-Consolidation Share for every 4,000,000 pre-Consolidation Shares, approved by 94.27% of Stockholders [1] - The effective date of the Consolidation is set for July 11, 2025, following unanimous approval from the Board of Directors [2] - Stockholders will receive a cash payment of $0.037 per pre-Consolidation Share for any fractional shares resulting from the Consolidation [3] - CLS has applied for voluntary delisting from the Canadian Securities Exchange, with the delisting expected to occur on the same date as the effective date of the Consolidation [4] - CLS Holdings USA Inc. operates as a diversified cannabis company, focusing on integrated cannabis production and retail, utilizing a patented method for cannabinoid extraction [5]

Core Viewpoint - MacKenzie Realty Capital, Inc. has announced a 1-for-10 reverse stock split to increase its share price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert ten existing shares into one new share, reducing the total shares outstanding from approximately 15,781,930 to about 1,578,192 [2]. - No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive cash equivalent to the fraction multiplied by the closing price prior to the split [2]. - The effective date of the reverse stock split will be announced at least two business days before implementation [4]. Group 2: Stockholder Information - Stockholders of record will not need to take action to receive post-split shares, as their positions will be automatically adjusted [3]. - Stockholders holding shares through banks or brokers should check with their respective institutions for specific procedures regarding the reverse stock split [3]. Group 3: Company Overview - MacKenzie Realty Capital, founded in 2013, is a West Coast-focused REIT aiming to invest at least 80% of its total assets in real property, with a portfolio consisting of approximately 50% multifamily and 50% boutique class A office properties [5]. - The company has consistently paid dividends since its inception and currently holds interests in 4 multifamily properties and 8 office properties, along with 2 multifamily developments [5].

Core Viewpoint - Cyclacel Pharmaceuticals, Inc. is implementing a 1-for-15 reverse stock split effective July 7, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][3]. Company Overview - Cyclacel is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology [4]. - The company is evaluating plogosertib, a PLK1 inhibitor, in patients with solid tumors and hematological malignancies as part of its epigenetic/anti-mitotic program [4]. - Cyclacel aims to build a diversified biopharmaceutical business with a pipeline of novel drug candidates targeting oncology and hematology indications [4]. Reverse Stock Split Details - The reverse stock split will convert every 15 shares of common stock into one share, with no fractional shares issued; any fractions will be rounded to the nearest whole number [2]. - The board of directors and stockholders approved the reverse stock split, which will reduce the number of shares from 23,759,475 to 1,583,965 [3]. - The new CUSIP number for the shares post-split will be 23254L876, and trading will continue under the symbol "CYCC" on The Nasdaq Capital Market [1][3].

Core Viewpoint - Boqii Holding Limited will terminate its Deposit Agreement and implement a reverse stock split, consolidating every 160 ordinary shares into one new ordinary share, with plans to list its Class A ordinary shares on NYSE American LLC [1][2] Company Actions - The termination of the Deposit Agreement was approved by shareholders on June 26, 2025 [1] - A reverse stock split will occur, consolidating every 160 ordinary shares into one new ordinary share [1] - The company plans to list its Class A ordinary shares on NYSE American LLC, replacing the American depositary shares (ADSs) [2] Company Overview - Boqii Holding Limited is a leading pet-focused platform in China, offering a wide selection of high-quality pet products [3] - The company provides products from global leading brands, local emerging brands, and its own private labels, including Yoken, Mocare, and D-cat [3] - Boqii's online sales platforms include Boqii Mall and flagship stores on third-party e-commerce platforms, enhancing customer access and shopping experience [3]